BioCryst pays $5M upfront in licensing deal for vision-loss treatment


A biotechnology company in Research Triangle Park has landed a licensing deal to pursue a treatment for vision loss related to diabetes.

Previous Truliant Federal Credit Union makes 3% trim in workforce
Next Austin scraps parking requirements as it targets affordability, reliance on public transit